This is an audio version of the Wikipedia Article:
For paithan own pro pa a fine on brand-name rhythm all senior writ menorah is a class one c anti-arrhythmic medication which treats illnesses associated with rapid heartbeats such as atrial and ventricular arrhythmias mechanism of action for cathinone works by slowing the influx of sodium ions into the cardiac muscle cells causing a decrease in excitability of
The cells for path inone is more selective for cells with a high rate but also blocks normal cells more than class iya or if for path enone differs from the prototypical class ic antiarrhythmic in that it has additional activity as a beta adrenergic blocker which can cause bradycardia and bronchospasm metabolism for cathinone is metabolized primarily in the liver
Because of its short half-life it requires dosing 2 or 3 times daily to maintain steady blood levels the long-term safety of propafenone is unknown because it is structurally similar to another anti-arrhythmic medicine flecainide similar cautions should be exercised in its use flecainide and propafenone like other antiarrhythmic drugs have been shown to increase
The occurrence of arrhythmias 5.3 percent for propafenone have a physician prescribing information primarily in patients with underlying heart disease however their use in structurally normal hearts is considered safe side effects side effects attributed to propafenone include hypersensitivity reactions lupus like syndrome agranulocytosis cns disturbances such as
Dizziness lightheadedness gastrointestinal upset a metallic taste in bronchospasm about 20% of patients discontinued the drug due to side effects initiation of therapy for cathinone generally needs to be started in a hospital setting to assure ecg monitoring of the patient there are many different dosages of propafenone depending on clinical presentation of the
Arrhythmia the treatment is generally begun with relatively high dosages 450 to 900 milligrams d decreasing to near 300 milligrams d in most western countries the accepted maximal dosage is 900 milligrams d for economic and patient convenience reasons some clinicians are starting certain antiarrhythmic agents in an outpatient setting for some patients no consensus
Exists regarding the safety of this practice and information is needed to determine which agents in which patients are appropriate for outpatient initiation of antiarrhythmic therapy from a clinical point of view this drug is used primarily in patients with relatively preserved myocardial function http colon slash slash wwa hr q gov slash clinic /e pcm / atrial some
Dot htm contraindications and cautions caution should be used in administrating for pathan owned in individuals with hepatic dysfunction asthma chf or bradycardia stereochemistry for pathan own contains a stereocenter and consists of two enantiomers this is a racemate ie a one-to-one mixture of r in the s form patent issues the patents for the rhythm all family
Of products are owned by reliant pharmaceuticals inc in liberty corner new jersey reliant acquired the patents from developer abbott laboratories inc in 2003 rhythm all was originally developed in europe and marketed by no pharmaceuticals both in europe and north america the product was taken over by abbott in 2001 when abbott purchased no relient pharmaceuticals
Filed a federal patent infringement lawsuit against generic drug maker parr pharmaceuticals inc on december 19 2006 the lawsuit filed in the federal district court for delaware seeks to prevent par from manufacturing a generic version of rhythm all par is seeking approval to do so from the us food and drug administration reliant’s patent for the drug was issued
In october 1997 and it expired in 2014 parr believes the patent is invalid according to its filing with the fda see also list of cardiac pharmaceutical agents references
Transcribed from video
Propafenone | Wikipedia audio article By wikipedia tts